Hagemeyer Group - NanoBiotechnology
Key terms: Molecular Imaging, Drug Delivery, Nanotechnology, Biotechnology
2023 group L-R: Thirimadura Mendis, Rong Xu, Edwina Jap, Christoph Hagemeyer, Peije Russell, Saeedreza Zeibishirejini, Bamlaku Walie. Absent: Tuan Nguyen, Be'eri Niego
Group Leader
Research Overview
Our main theme is the development of "bio-better" antibodies with added functionality for the treatment of thrombosis, inflammation, diabetes and cancer. Using specifically modified recombinant antibodies we can deliver small molecules, therapeutic oligos, proteins and nanoparticles with high precision and reduced adverse effects. We can achieve this with a new bio-enzymatic conjugation method allowing site-specific attachment of nano-sized delivery scaffolds without affecting antibody function. We are also active in the molecular imaging area. Using targeted natural nanoparticles, we would like to significantly increase the number of imaging labels per antibody in MRI and PET/SPECT as well as photoacoustic and fluorescence imaging. This can increase the detection limit of current approaches.
Prof Christoph Hagemeyer and Dr Erik Westein explain the research to stop pathological blood clotting. See video
Project Opportunities
- Targeted virus particles for gene therapy
- Single-chain antibody-targeted nanoparticles for therapy and diagnosis
- Recombinant agents for efficient and safe anticoagulation as well as thrombolysis
For current project opportunity descriptions please visit our Honours page
Current Grants
- NHMRC Ideas Grant 2037640 (2025-28): A first-in-class anti-thrombotic therapy targeting blood flow activated von Willebrand Factor. CIs: Hagemeyer, Rosengarten, Ruggeri, Carberry, Niego.
- Breakthrough T1D (UK) Steve Morgan Foundation T1D Grand Challenge Grant 1-SRA-2024-1609-M-N (2025-26): An artificial pancreas nano sugar for the treatment of diabetes. CIs: Hagemeyer, Xu, Caruso, Cavalieri, Cowley, Cooper.
- Breakthrough T1D (Aus) SPARC Grant 201311708 (2025-26): Novel treatment for type-1 diabetes. CIs: Hagemeyer, Xu, Caruso, Cavalieri, Cooper.
- CASS Grant 12068 (2025-26): Development of natural nanoparticles for drug delivery into the brain. CIs: Niego, Cavalieri, Xu, Hagemeyer.
- Diabetes Australia Millennium Award Y25M1-Xuro (2025-26): Engineering an artificial pancreas for the treatment of diabetes. CIs: Xu, Hagemeyer, Cavalieri, Caruso, Cooper.
- European Commission HORIZON-MSCA Grant 101182883 (2025-2028): Programmable bionanomaterials with protein-controlled behavior. CIs: Bertucci, De Cola, Teesalu, Patiño Padial, Miki, Hagemeyer, Peinetti, Javor, Sailor.
- ARC Grant IC230100046 (2024-28): ARC ITTC for the Development of Advanced Radiochemical Technologies (DART). CIs: Robinson, Donnelly, Rendina, McIntosh, Hagemeyer, Tuck, Andrews, Alt, Ritchie, Turner, Chan, Aulsebrook, Hutton, White, Rutledge, New, Ackermann.
- Monash-Helmholtz Laboratory for Radio-Immuno-Theranostics (MHELTHERA) together with Helmholtz Zentrum Dresden Rossendorf, Germany (2021-2025). Monash CIs: Hagemeyer, Aulsebrook, Alt, Andrews, Egan, Jupp, Ritchie, Robinson, Tuck.